Your Product

Your Product

Back to main menu

Your Product

Services tailored to your product, ensuring the right development path, scalable processes, and consistent manufacturing outcomes.

Learn more
Your Stage

Your Stage

Back to main menu

Your Stage

At each stage, new challenges emerge. A single team and site ensure continuity and consistent execution across the product lifecycle.

Learn more
Our Services

Our Services

Back to main menu

Our Services

Integrated CDMO services designed for seamless progression from development through commercial manufacturing, under global regulatory standards.

Learn more
Resources

Resources

Back to main menu

Resources

Technical insights, practical guidance, and applied expertise to support decision‑making at every stage.

See all resources
About Us

About Us

Back to main menu

About Us

An overview of Groupe PARIMA, our mission, and our expertise in supporting the pharmaceutical industry.

Learn more
    En
    English
    Contact us

    Late-Stage

    Groupe PARIMA supports late-stage programs by refining early results into repeatable and scalable GMP execution. 

    AdobeStock_1862304399 1
    Built for repeatability

    Where robust products emerge

    Groupe PARIMA supports late‑stage programs through tech transfer and validation to secure process consistency and regulatory readiness. Our single‑site finalizes manufacturing processes, completes process and analytical validation, and generates stability data.

    Talk to our experts

    Scale-up and validation secured

    We work closely with your team, providing direct access to scientific experts and integrated analytical and production capabilities to secure validation execution and submission timelines.

    Reduce scale‑up surprises

    Use prior knowledge and confirmatory studies to demonstrate formulation and process robustness at commercial‑relevant batch sizes.

    Strengthen methods 

    Develop, validate, and transfer analytical methods, generating stability data that supports validation, regulatory submission, and lifecycle management.

    Maintain reliable GMP Batches

    Support exhibit and validation batches through controlled GMP manufacturing and packaging aligned with PPQ and submission timelines.

    Validation driving reliable supply

    Groupe PARIMA delivers late‑stage analytical and manufacturing capabilities within a single‑site model. We support tech transfer and validation activities by confirming scale‑up readiness, executing validated analytical methods, and generating technical evidence required for regulatory submission and reliable GMP supply.

    01
    Card 01

    QbD and DoE approach 

    We use a Quality by Design approach supported by Design of Experiments to confirm CMA, CPP, and CQA and demonstrate process robustness.

    02
    Card 02

    Tech transfer and validation

    Establish and confirm manufacturing and packaging processes through controlled tech transfer and validation for commercial‑scale production.

    03
    Card 03

    Method robustness and stability studies

    Our in-house laboratory executes method development, validation, and transfer, plus stability programs and microbiology testing. 

    Our Services

    Late-stage confirms methods are validated for robustness, and stability evidence is generated to support consistent GMP clinical supply and regulatory submission.

    01
    Layer_1-1
    Product Development

    Use QbD and DoE to refine the process for clinical scale.

    Learn more
    02
    Icons-1
    Analytical Services

    Strengthen method robustness and stability with in-house chemistry and microbiology testing.

    Learn more
    03
    Icons (1)-1
    Manufacturing & Packaging

    Adjust batch size and packaging formats to support Phase II supply as study needs evolve.

    Learn more

    We work closely with your team to execute late‑stage programs with control, consistency, and predictable performance at scale.

    Resources

    Explore resources on tech transfer, validation, and analytical and stability data supporting consistent GMP supply.

    Groupe PARIMA
    2026/04/27
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Resources
    Groupe PARIMA
    2026/03/18
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Resources
    Groupe PARIMA
    2025/10/23
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Resources
    Groupe PARIMA
    2026/04/27
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Resources
    Groupe PARIMA
    2026/03/18
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Resources
    Groupe PARIMA
    2025/10/23
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Resources

    See all Resources

    Contact us

    Secure your late-stage execution.

    Tell us where your program is today, and we’ll support controlled tech transfer and validation through scale‑up and commercialization.